Clinical Cancer Research, Vol 4, Issue 12 3083-3088, Copyright © 1998 by American Association for Cancer Research

ARTICLES

A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent

SL Winski, RH Hargreaves, J Butler and D Ross
Department of Pharmaceutical Sciences, School of Pharmacy and Cancer Center, University of Colorado Health Sciences Center, Denver 80262, USA.

NAD(P)H:quinone oxidoreductase (NQO1; DT-diaphorase) is elevated in certain tumors, such as non-small cell lung cancer (NSCLC). Compounds such as mitomycin C and streptonigrin are efficiently bioactivated by NQO1 and have been used in an enzyme-directed approach to chemotherapy. Previously, 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinone (MeDZQ) was identified as a potential antitumor agent based on its high rate of bioactivation by human NQO1 and its selective cytotoxicity to cells containing elevated NQO1. RH1, a water-soluble analogue of MeDZQ synthesized in this work, was a better substrate for recombinant human NQO1 than the parent compound. RH1 was, correspondingly, more cytotoxic to human tumor cells expressing elevated NQO1 activity (H460 NSCLC and HT29 human colon carcinoma), as measured by 3-(4,5-dimethylthiazol-2,5-diphenyl)tetrazolium assay, than it was to cells deficient in NQO1 activity (H596 NSCLC and BE human colon carcinoma). RH1 exhibited a greater selective toxicity (ratio of IC50s in H596:H460 and BE:HT29) to cells with elevated NQO1 activity relative to MeDZQ. Additionally, we report the establishment of a stable line of BE human colon carcinoma cells transfected with wild-type human NQO1 (BE-NQ7). BE cells are devoid of NQO1 activity due to a homozygous point mutation in the NQO1 gene. In comparison to the parental cell line, RH1, MeDZQ, and mitomycin C were significantly more cytotoxic to BE-NQ7 cells (17-, 7-, and 3-fold, respectively), confirming that the presence of NQO1 is sufficient to increase cytotoxicity of these antitumor quinones. These data suggest that RH1 may be an effective NQO1-directed antitumor agent for the therapy of tumors with elevated NQO1 activity, such as NSCLC.

This article has been cited by other articles:

				W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross The Bioreduction of a Series of Benzoquinone Ansamycins by NAD(P)H:Quinone Oxidoreductase 1 to More Potent Heat Shock Protein 90 Inhibitors, the Hydroquinone Ansamycins Mol. Pharmacol., October 1, 2006; 70(4): 1194 - 1203. [Abstract] [Full Text] [PDF]

				D. L. Dehn, D. Siegel, K. S. Zafar, P. Reigan, E. Swann, C. J. Moody, and D. Ross 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol. Cancer Ther., July 1, 2006; 5(7): 1702 - 1709. [Abstract] [Full Text] [PDF]

				J. Gao, K. Kashfi, X. Liu, and B. Rigas NO-donating aspirin induces phase II enzymes in vitro and in vivo Carcinogenesis, April 1, 2006; 27(4): 803 - 810. [Abstract] [Full Text] [PDF]

				W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross Formation of 17-Allylamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition Cancer Res., November 1, 2005; 65(21): 10006 - 10015. [Abstract] [Full Text] [PDF]

				D. L. Dehn, S. H. Inayat-Hussain, and D. Ross RH1 Induces Cellular Damage in an NAD(P)H:Quinone Oxidoreductase 1-Dependent Manner: Relationship between DNA Cross-linking, Cell Cycle Perturbations, and Apoptosis J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 771 - 779. [Abstract] [Full Text] [PDF]

				T. H. Ward, S. Danson, A. T. McGown, M. Ranson, N. A. Coe, G. C. Jayson, J. Cummings, R. H.J. Hargreaves, and J. Butler Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone Clin. Cancer Res., April 1, 2005; 11(7): 2695 - 2701. [Abstract] [Full Text] [PDF]

				N. Cenas, H. Nivinskas, Z. Anusevicius, J. Sarlauskas, F. Lederer, and E. S. J. Arner Interactions of Quinones with Thioredoxin Reductase: A CHALLENGE TO THE ANTIOXIDANT ROLE OF THE MAMMALIAN SELENOPROTEIN J. Biol. Chem., January 23, 2004; 279(4): 2583 - 2592. [Abstract] [Full Text] [PDF]

				D. L. Dehn, D. Siegel, E. Swann, C. J. Moody, and D. Ross Biochemical, Cytotoxic, and Genotoxic Effects of ES936, a Mechanism-Based Inhibitor of NAD(P)H:quinone Oxidoreductase 1, in Cellular Systems Mol. Pharmacol., September 1, 2003; 64(3): 714 - 720. [Abstract] [Full Text] [PDF]

				D. L. Gustafson, D. Siegel, J. C. Rastatter, A. L. Merz, J. C. Parpal, J. K. Kepa, D. Ross, and M. E. Long Kinetics of NAD(P)H:Quinone Oxidoreductase I (NQO1) Inhibition by Mitomycin C in Vitro and in Vivo J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1079 - 1086. [Abstract] [Full Text] [PDF]

				A. Anwar, D. Siegel, J. K. Kepa, and D. Ross Interaction of the Molecular Chaperone Hsp70 with Human NAD(P)H:Quinone Oxidoreductase 1 J. Biol. Chem., April 12, 2002; 277(16): 14060 - 14067. [Abstract] [Full Text] [PDF]

				F. Zappa, T. Ward, J. Butler, E. Pedrinis, and A. McGown Overexpression of NAD(P)H:quinone oxidoreductase 1 in Human Reproductive System J. Histochem. Cytochem., September 1, 2001; 49(9): 1187 - 1188. [Abstract] [Full Text] [PDF]

				L. L. Xu, J. C. Wain, D. P. Miller, S. W. Thurston, L. Su, T. J. Lynch, and D. C. Christiani The NAD(P)H:quinone Oxidoreductase 1 Gene Polymorphism and Lung Cancer: Differential Susceptibility Based on Smoking Behavior Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 303 - 309. [Abstract] [Full Text]

				D. Siegel, A. Anwar, S. L. Winski, J. K. Kepa, K. L. Zolman, and D. Ross Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1 Mol. Pharmacol., February 1, 2001; 59(2): 263 - 268. [Abstract] [Full Text]

				S. Y. Sharp, L. R. Kelland, M. R. Valenti, L. A. Brunton, S. Hobbs, and P. Workman Establishment of an Isogenic Human Colon Tumor Model for NQO1 Gene Expression: Application to Investigate the Role of DT-Diaphorase in Bioreductive Drug Activation In Vitro and In Vivo Mol. Pharmacol., November 1, 2000; 58(5): 1146 - 1155. [Abstract] [Full Text]

				L. P. Schelonka, D. Siegel, M. W. Wilson, A. Meininger, and D. Ross Immunohistochemical Localization of NQO1 in Epithelial Dysplasia and Neoplasia and in Donor Eyes Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1617 - 1622. [Abstract] [Full Text]